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Pathway Targets to Explore in the Treatment of Non-small
Cell Lung Cancer
Glen J. Weiss, MD,*† and Chris Kingsley, PhD†
Introduction: With a 5-year survival rate of only 16%, improve-
ments in therapeutic strategies for the treatment of non-small cell
lung cancer (NSCLC) are still warranted. Published prognostic gene
expression classification signatures in NSCLC overlap poorly across
studies. We hypothesized that different NSCLC microarray datasets
will share common pathways leading to the identification of new
targets for therapeutic development.
Methods: Per gene mean expression fold change ratios were calcu-
lated from 7 publicly-available microarray datasets consisting of a
total of 725 profiled samples. This was followed by mapping of
differentially expression genes into functionally annotated biologic
pathways using Ingenuity pathway analysis software. Common
pathways containing genes whose expression levels differed be-
tween phenotypic classes defined by NSCLC cases and/or histology,
pathologic stage, and gender were determined.
Results: Several significant common pathways overlapping these
datasets were identified in silico. One of which, Leukocyte Extrav-
asation Signaling pathway, includes targeted agents such as ima-
tinib, dasatinib, and temozolomide currently under exploration in
NSCLC trials. The remaining pathways have targets with few drugs
developed or under development in cancer therapeutics. Comparison
of pathways derived from Eastern versus Western population data-
sets revealed several differing targets and potential target drugs.
Conclusion: This in silico pathway exploration in NSCLC warrants
further investigation and could open the door to potential new
therapeutics that might improve NSCLC patient outcomes. This
strategy can be applied to other cancer types.
Key Words: Gene expression profiling, Non-small cell lung cancer,
Pathway analysis, In silico.
(J Thorac Oncol. 2008;3: 1342–1352)
Lung cancer is the most common cause of cancer mortalityin the world, with an estimated 1.18 million new cases
annually.1 Non-small cell lung cancer (NSCLC) represents
approximately 88% of lung cancer cases,2 of which approx-
imately 75% represent advanced-stage disease. Recent treat-
ment advances for advanced NSCLC include the addition of
bevacizumab to chemotherapy in nonsquamous histology3,4
and the Food and Drug Administration (FDA) approval of
three agents for second-line therapy.5–7 However, the 5-year
survival rate for all NSCLC is a disappointing 16%,8 neces-
sitating further improvement in therapeutic strategies. Several
prognostic gene expression signatures in NSCLC have been
reported, but reproducibility across studies has been poor.9
While not fully elucidated, possible explanations include
differences in microarray platforms, processing of material,
patient cohorts, and/or methods of analysis.10 If these differ-
ent microarray datasets share perturbations in common path-
ways, however, identification of these commonalities may
lead to the identification of new and possibly unrealized
targets for NSCLC treatment.
METHODS
Microarray datasets from Duke University (Duke)11 were
downloaded as text files prenormalized by the MAS5 algo-
rithm.12,13 Microarray data sets from the Samsung Medical
Center (Korea)14 were downloaded as text files prenormalized
using the GC Robust Multi-array Average algorithm.15
Microarray datasets from the Dana-Farber Cancer In-
stitute,16 Taipei Veterans General Hospital (Taipei),17 Uni-
versity of Duesseldorf (Germany),18 University of Michigan
(Michigan),19 and Expression Project for Oncology (ExpO)20
were downloaded as raw Affymetrix.cel files and normalized
using the Robust Multichip Average method21 as imple-
mented in the Affymetrix Expression Console v1.1.
For all datasets, small cell and carcinoid lung cancer
samples were excluded and per gene mean expression fold
change ratios were separately calculated from the remaining
samples of each dataset. When the appropriate clinical anno-
tations were available, fold changes were calculated for lung
cancer versus normal lung, adenocarcinoma (AC) versus
squamous cell carcinoma (SCC), early-stage (stage I–II)
versus late-stage (stage III–IV), and male versus female.
Fold changes greater than 2 or less than 0.5 were
analyzed in a functional annotation and pathway database
using Ingenuity pathway analysis (IPA).22 Common path-
ways significantly perturbed when comparing NSCLC ex-
pression profiles of differing histologic class, pathologic
stage, and gender were determined. Canonical pathways were
interrogated, and p-values from all performed hypothesis
tests were pooled and adjusted by the method of Benjamini
and Hochberg (as implemented in the R/bioconductor multi-
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test package23) to estimate the False Discovery Rate (FDR).24
Those pathways with an estimated FDR less than 0.05 were
recorded. When two or more institutions shared significant
canonical IPA pathway results by category (lung cancer
versus normal tissue; AC versus SCC; early-stage versus
late-stage; or male versus female), the pathway was annotated
as a “common pathway.” Common pathways were ranked
according to the number of datasets in which the pathway was
significantly perturbed and were interrogated for the presence
of known drug targets and known oncogenes.
RESULTS
Clinical characteristics of profiled samples (n  725)
are summarized in Table 1. Age, gender, ethnicity, stage,
histology, and pack-years of cigarette smoking were included
when available. Dana-Farber Cancer Institute, Michigan, and
Taiwan datasets comprise primarily ACs and include more
women than men. Duke, Korea, and ExpO datasets lacked
profiling of normal lung tissue.
Several common pathways were identified in silico as
significantly affected among these datasets using IPA. Table
2 lists the pathways with an estimated FDR less than 5%
among the datasets, while Table 3 lists the shared pathways
among the datasets. No significant pathways were identified
in any of the clinical annotation comparisons in the Korea
dataset. In the lung cancer versus normal tissue comparison,
there were two common pathways shared by at least two
datasets—Leukocyte Extravasation Signaling (Figure 1) and
Coagulation System (Figure 2). Targets in these two path-
ways and their respective potential targeting drugs are in-
cluded in Table 4. Imatinib,25 dasatinib,26 and temozolo-
mide27 are potential drugs for the Leukocyte Extravasation
Signaling pathway, targeting ABL/c-Kit (imatinib) and Src
(dasatinib and temozolomide). All three of these agents are or
have been studied in NSCLC clinical trials28 and are FDA
approved agents in other tumor types. Possible drug targets in
the Coagulation System pathway include Factor Xa, Factor
IIa, and SERPINC1, which could potentially be treated with
available antiheparinase agents.
Acute Phase Response Signaling (Figure 3 supplemen-
tary section) and Complement System pathways are affected
in four datasets comparing AC versus SCC. The Acute Phase
Response Signaling pathway includes mTOR, c-RAF, and
TNF targets, for which drugs such as everolimus, sorafenib,
and thalidomide have been FDA approved for cancer treat-
ment and are currently being explored in NSCLC clinical
trials28 (thalidomide studies are now closed). In the Comple-
ment System pathway, eculizumab is listed as a potential
agent, which targets C5, C5a, and C5b, and is FDA approved
for the treatment of paroxysmal nocturnal hemoglobinuria.
Acute Phase Response Signaling and LPS/IL-1 medi-
ated inhibition of Retinoid X Receptor (RXR) function are
significant in two datasets comparing males versus females.
The LPS/IL-1 Mediated Inhibition of RXR Function pathway
includes the target, RXR, for which drugs such as bexaro-
tene has been studied in NSCLC clinical trials.29,30
TABLE 1. Clinical Characteristics of Analyzed NSCLC Specimens
Clinical
Characteristic
Michigan Dataset
n  96 Including
10 Normal Lung
DFCI Dataseta
n  228
Including 17
Normal Lung
Duke Dataset
n  111
Germany Dataset
n  25 Including
5 Normal Lung
ExpO Dataset
n  69
Korean Dataset
n  138
Taiwan Dataset
n  58
Including 30
Normal Lung
Age (range) N/A 33–88 N/A 45–80 40–90b 37–82 N/A
Gender
Female/male/(N/A) 51/35 (0) 102/73 (34) 47/64 (0) 4/16 (0) 20/49 (0) 34/104 (0) 22/5 (1)
Ethnicity N/A N/A N/A N/A
Caucasian 64 — —
Asian 2 138 28
Hispanic 1 — —
Native American 1 — —
Stage N/A N/A N/A
Stage I 67 107 67 30
Stage II — 33 18 8
Stage III 19 15 21 7
Stage IV — 19 5 3
Histology
AC 86 190 58 10 15 62 27
SCC — 21 53 10 34 76
Other NSCLC — — — — 20 — 1
Pack years (range)b 0–160 0–140 N/A N/A 11–65c N/A N/A
Array platform Affymetrix Affymetrix Affymetrix HG Affymetrix Human Affymetrix HG Affymetrix HG Affymetrix
Hu6800 U95Av2 U133 Plus 2.0 HG-focus target U133 Plus 2.0 U133 Plus 2.0 U133A
a Includes 51 replicates of profiled samples.
b Age range listed by 10 yr span, specific ages not available.
c Pack years range listed by 5 yr span, specific pack years smoked not available.
N/A, not available; AC, adenocarcinoma; SCC, squamous cell carcinoma; Other NSCLC, other non-small cell lung cancer subtypes, DFCI, Dana-Farber Cancer Institute.
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To explore differences in potential targets among West-
ern and Eastern populations, the significant pathways identi-
fied in the Taiwan and/or Korea (Eastern) datasets were
compared with the remaining datasets profiled in Western
countries (Western). In lung cancer versus normal lung,
pathways exclusive to Western datasets included: Acute
Phase Response Signaling, C21-Steroid Hormone Metabo-
lism, Hepatic Fibrosis/Hepatic Stellate Cell Activation, Pen-
tose and Glucuronate Interconversions, while pathways ex-
clusive to Eastern datasets included: Cell Cycle: G2/M DNA
Damage Checkpoint Regulation. The Hepatic Fibrosis/He-
patic Stellate Cell Activation pathway includes epidermal
growth factor receptor (EGFR) and vascular endothelial
growth factor (VEGF) as targets, with erlotinib and cetux-
imab (EGFR) and bevacizumab (VEGF), respectively, as
FDA approved agents in the treatment of NSCLC or other
cancers. When comparing AC versus SCC, there were no
pathways exclusive to Eastern datasets. Pathways exclusive
to Western datasets were the Acute Phase Response Signal-
ing, Antigen Presenting Pathway, Coagulation System, Com-
plement System, and Leukocyte Extravasation Signaling. For
all of these pathways, drugs have been identified that target
one or more pathway components (pathway target). Pathway
targets for the Antigen Presenting Pathway, not listed previ-
ously, includes LMPX also known as PSMB5 (proteasome
(prosome, macropain) subunit, beta type, 5) for which bort-
ezomib is a potential targeting drug. When comparing male
versus female, there were no pathways exclusive to Eastern
datasets, while the pathways exclusive to Western datasets
are listed in Table 2, Male versus Female Pathway.
DISCUSSION
Utilizing publicly available NSCLC gene expression
datasets, we identified pathways in silico perturbed in various
clinical comparisons in at least two datasets including: Co-
agulation System (lung cancer versus normal lung, AC versus
SCC, early-stage versus late-stage); Acute Phase Response
Signaling (AC versus SCC, early-stage versus late stage, and
male versus female); Complement System (AC versus SCC);
Leukocyte Extravasation System (lung cancer versus normal
lung); and LPS/IL-1 Mediated Inhibition of RXR Function
(male versus female) (Table 3). Several drug targeting mem-
bers of the Acute Phase Response Signaling pathway
(everolimus and sorafenib) are actively being evaluating in
ongoing clinical trials and already FDA approved in other
cancers. C-Src, a pathway target in the Leukocyte Extrava-
sation Signaling pathway, acts as an upstream activator and
downstream mediator of the epidermal growth factor recep-
tor.31 By immunohistochemical analysis of 370 NSCLC bi-
opsy samples, expression of phosphorylation of Src family
kinase was shown to be present in 33% of cases.31 Since Src
is commonly expressed in NSCLC, further development of
TABLE 2. Significant Pathways by Clinical Characteristics
Lung cancer vs. normal lung
Pathway
Acute phase response signaling (1)
C21-steroid hormone metabolism (1)
Cell cycle: G2/M DNA damage checkpoint regulation (2)
Coagulation system (2, 3)
Hepatic fibrosis/hepatic stellate cell activation (3)
Leukocyte extravasation signaling (2, 3)
Pentose and glucuronate interconversions (4)
AC vs. SCC
Pathway
Acute phase response signaling (3–6)
Antigen presentation pathway (3)
Coagulation system (3–5)
Complement system (3–6)
Leukocyte extravasation signaling (3)
Early-stage vs. late-stage
Pathway
Acute phase response signaling (5, 6)
Coagulation system (5, 6)
Complement system (5)
Glucocorticoid receptor signaling (6)
Hepatic cholestasis (6)
Hepatic fibrosis/hepatic stellate cell activation (6)
IL-6 Signaling (6)
LPS/IL-1 mediated inhibition of RXR function (6)
LXR/RXR activation (6)
Metabolism of Xenobiotics by cytochrome P450 (6)
p38 MAPK signaling (6)
PXR/RXR activation (6)
Male vs. female
Pathway
Acute phase response signaling (1, 5)
Androgen and estrogen metabolism (6)
Ascorbate and Aldarate metabolism (3)
Glutathione metabolism (6)
Hepatic cholestasis (5)
LPS/IL-1 mediated inhibition of RXR function (5, 6)
LXR/RXR activation (5)
Metabolism of Xenobiotics by cytochrome P450 (6)
Pentose and glucuronate interconversions (6)
Retinol metabolism (6)
Starch and sucrose metabolism (6)
Wnt/-catenin signaling (6)
Xenobiotic metabolism signaling (5, 6)
1, Michigan; 2, Taiwan; 3, Germany; 4, DFCI; 5, Duke; 6, ExpO; 7, Korea.
TABLE 3. Pathways Ranked by Commonalities
Lung cancer vs. normal lung 2 of 5
Coagulation system
Leukocyte extravasation signaling
AC vs. SCC 4 of 5 AC vs. SCC 3 of 5
Acute phase response signaling Coagulation system
Complement system
Early-stage vs. late-stage 2 of 5
Acute phase response signaling
Coagulation system
Male vs. female 2 of 5
Acute phase response signaling
LPS/IL-1 mediated inhibition of RXR function
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agents targeting Src could hold promise. Indeed, dasatinib
which has anti-Src activity is under clinical trial investigation
in NSCLC.28 A drug targeting RXR (LPS/IL-1 Mediated
Inhibition of RXR Function pathway), bexarotene was eval-
uated in combination with first-line chemotherapy in ad-
vanced NSCLC.29,30 While this agent did not improve overall
survival, interestingly, male patients developing hypertriglyc-
eridemia in both studies seemed to derive the most benefit.
Interestingly, no traditional tumor cytotoxic or targeted
agents are listed for the Coagulation System pathway. How-
ever, preclinical data suggests that antiheparinase agents
(heparin and low molecular weight heparin) that target path-
way members Factor Xa, Factor IIa, and SERPINC1 may
mitigate tumor progression and metastasis.32,33
We identified pathways that are specifically affected in
either Eastern or Western populations by separately analyzing
patient samples from each geographical region. There were a
number of differences, which may account for diverging
results from NSCLC clinical trials. From these differences in
pathway perturbations, agents currently under evaluation in
NSCLC that may work preferentially better in Western pop-
ulations include: everolimus, sorafenib (Acute Phase Re-
sponse Signaling), erlotinib, cetuximab, and bevacizumab
(Hepatic Fibrosis/Hepatic Stellate Cell Activation), imatinib,
dasatinib, temozolomide (Leukocyte Extravasation Signal-
ing), and bortezomib (Antigen Presenting Pathway). Lack of
obvious preferential pathways with drug targets favoring
Eastern populations may be due to lower frequency of sig-
nificant perturbations in those Eastern datasets, especially
with the Korean dataset not contributing to this analysis.
Interestingly, recent trial results show improved results with
cetuximab in combination with first-line chemotherapy in
advanced NSCLC in Western populations,34 while it is well-
known that erlotinib is more likely to have beneficial results
in Eastern populations.35 Some of the differences for these
results may be that cetuximab is a monoclonal antibody,
FIGURE 1. Leukocyte Extravasation Signaling pathway and potential targeting drugs. This illustration details the interactions
of targets (shapes in blue) with the potential targeting agents (ellipse with Rx followed by drug name) connected by solid
line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are depicted. Types of
interaction relationships are annotated in the figure. Additional drugs for targets annotated in the figure include the following:
Target Drug
Src AZM-475271
ABL temozolomide
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FIGURE 2. Coagulation System pathway and potential targeting drugs. This illustration details the interactions of targets (shapes in
blue) with the potential targeting agents (ellipse with Rx followed by drug name) connected by solid line(s). Additional proteins and tar-
gets in this pathway (for which no current drug has been identified) are depicted. Types of interaction relationships are annotated in the
figure. Additional drugs for targets annotated in the figure include the following:
Target(s) Drug(s)
F10, F10a, SERPINC1 Fondaparinux
F10, F10a DPC 423, delogoparin, heparin, RPR 120844, rivaroxabin, coagulation factor IX, idraparinux, tifacogin, RPR
208566, coagulation factor VIIa, dalteparin, antihemophilic factor
F2, F2a, F2R Argatroban
Plasmin PLG Epsilon-amino caproic acid, reteplase, tissue plasminogen activator
F2, F2a Desirudin, dabagatran etexilate reteplase
IL-6 Tocilizumab
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TABLE 4. Leukocyte Extravasation Signaling and Coagulation System Pathway Targets and Targeting Agents
Leukocyte Extravasation Signaling Coagulation System
Target Description Potential Drug Target Description Potential Drug
ABL v-abl Abelson murine leukemia
viral oncogene homolog 1
Imatinib, temozolomide Alpha-2-macroglobulin
ACTN
Ca2 Coagulation factor X Dalteparin, heparin, enoxaparin,
rivaroxaban
Deligoparin, idraparinux, tifacogin,
RPR 120844
RPR 208566, DPC 423,
fondaparinux
CAM Coagulation factor XI
cAMP Coagulation factor XII
CAS Breast cancer antiestrogen
resistance 1
CD43 Sialophorin (leukosialin, CD43) Coagulation factor XIII, A1 polypeptide
CD44 CD44 molecule (Indian blood
group)
Coagulation factor II (thrombin) Enoxaparin, desirudin, dabigatran
etexilate, argatroban
Bivalirudin, lepirudin
CD99 CD99 molecule Coagulation factor II (thrombin)
receptor
Chrysalin, argatroban, bivalirudin
Cdc42 Cell division cycle 42 (GTP
binding protein, 25 kDa)
Coagulation factor III
CDH5 Cadherin 5, type 2, VE-cadherin
(vascular epithelium)
F3-F5-F7-F10
Cortactin Cortactin F3-F5-F8-F10
CRK
CTNNA F3-F7-F10
CTNNB1 Catenin (cadherin-associated
protein), beta 1, 88 kDa
F3-F8-F10
CTNND1 Catenin (cadherin-associated
protein), delta 1
Coagulation factor V Drotrecogin alfa
CXCR4 Chemokine (C-X-C motif)
receptor 4
JM 3100 Coagulation factor VII
CYBA Cytochrome b-245, alpha
polypeptide
Coagulation factor VIII, procoagulant
component (hemophilia A)
Drotrecogin alfa
Cyba-Ncf1c-
Ncf2-
Nox-
Ncf4
Coagulation factor IX
DAG
EPAC Fibrin (cross-link polymer)
ERM Kininogen 1
F-Actin Kallikrein B, plasma (Fletcher factor) 1 Aprotinin, DX88
FAK PTK2 protein tyrosine kinase 2 Plasminogen Tissue plasminogen activator,
tenecteplase, aprotinin
Epsilon-amino caproic acid, reteplase
Fer Fer (fps/fes related) tyrosine
kinase (phosphoprotein NCP94)
Protein C (inactivator of coagulation
factors Va and VIIIa)
GNAI Protein S (alpha)
H2O2 Serpin peptidase inhibitor, clade A,
member 1
CAM1 Intercellular adhesion molecule 1
(CD54), human rhinovirus
receptor
Serpin peptidase inhibitor, clade A,
member 5
CAM3 Intercellular adhesion molecule 3 Serpin peptidase inhibitor, clade C,
member 1
Enoxaparin, SR-123781A,
fondaparinux
P3 Serpin peptidase inhibitor, clade D,
member 1
(Continued)
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TABLE 4. (Continued)
Leukocyte Extravasation Signaling Coagulation System
Target Description Potential Drug Target Description Potential Drug
ITGA4 Integrin, alpha 4 (antigen
CD49D, alpha 4 subunit of
VLA-4 receptor)
Natalizumab Serpin peptidase inhibitor, clade E,
member 1
Drotrecogin alfa
Itga4-Itgb1 Serpin peptidase inhibitor, clade F,
member 2
ITGAL Integrin, alpha L (antigen
CD11A (p180), lymphocyte
function-associated antigen 1;
alpha polypeptide)
Efalizumab Tissue factor pathway inhibitor
Itgal-Itgb2 Thrombomodulin
ITGAM Integrin, alpha M (complement
component 3 receptor 3
subunit)
Plasminogen activator, tissue
Itgam-Itgb2 Plasminogen activator, urokinase
ITGB1 Integrin, beta 1 (fibronectin
receptor, beta polypeptide,
antigen CD29 includes MDF2,
MSK12)
Plasminogen activator, urokinase
receptor
ITGB2 Integrin, beta 2 (complement
component 3 receptor 3 and 4
subunit)
von Willebrand factor
JAM1 F11 receptor
JAM2 Junctional adhesion molecule 2
JAM3 Junctional adhesion molecule 3
JNK
MEK2 Mitogen-activated protein kinase PD 0325901
Kinase 2
MEKK4 Mitogen-activated protein kinase
kinase kinase 4
MLLT4 Myeloid/lymphoid or mixed-
lineage leukemia (trithorax
homolog, Drosophila);
translocated to, 4
MMP
MMP9 Matrix metallopeptidase 9
(gelatinase B, 92kDa
gelatinase, 92kDa type IV
collagenase)
MYL6 Myosin, light chain 6, alkali,
smooth muscle and non-
muscle
NCF1 Neutrophil cytosolic factor 1C
pseudogene
NCF2 Neutrophil cytosolic factor 2
(65kDa, chronic granulomatous
disease, autosomal 2)
NCF4 Neutrophil cytosolic factor 4,
40kDa
NOX
p38 MAPK
PECAM1 Platelet/endothelial cell adhesion
molecule (CD31 antigen)
PI3K
PIP2
PKC
PLC
PSGL-1 Selectin P ligand
(Continued)
Weiss and Kingsley Journal of Thoracic Oncology • Volume 3, Number 11, November 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1348
while erlotinib is a tyrosine kinase inhibitor. Tyrosine kinase
inhibitors may be better suited in tumors with EGFR muta-
tions, which are more prevalent in Eastern patients with
NSCLC. Further work to resolve these differences are
awaited. The remaining pathways contain targets with few
drugs developed or under development as cancer therapeutics
in other tissue types, but may hold promise for therapeutic
development strategies in advanced NSCLC.
CONCLUSION
Data mining several gene expression datasets to explore
pathway commonalities can lead to the identification of new
targets that may be worth further exploration for therapeutic
development in the treatment of NSCLC. This type of anal-
ysis can also be applied to other tumor types, potentially
benefiting cancer patients.
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FIGURE 3. (Supplementary Section). Acute Phase Response Signaling pathway and potential targeting drugs This illustration
details the interactions of targets (shapes in blue) with the potential targeting agents (ellipse with Rx followed by drug name)
connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are
depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets annotated in the figure
include the following:
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Target(s) Drug(s)
TNF Adalimumab, etanercept, infliximab, CDP870, golimumab
IL1R1 Anakinra
mTOR AP23573, temsirolimus, tacrolimus
KLKB1 Aprotinin, DX88
C5 Eculizumab
F2 Enoxaparin, desirudin, dabigatran etexilate, bivalirudin, lepirudin
GCR Rimexolone, medrysone, clocortolone pivalate, diflorasone diacetate, fluorometholone, other corticosteroids, ORG 34517, miconazole
PLG Tissue plasminogen activator, tenecteplase, aprotinin, epsilon-amino caproic acid,
Reteplase
IL-6 Tocilizumab
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